←
Axel S. Merseburger3,784 posts
Axel S. Merseburger avatar✓

Axel S. Merseburger ✓

@amerseburger

Professor of Urology, Chairman Department of Urology, EiC "Aktuelle Urologie", Editor World Journal of Urology. Chairman EUSP, EAU-Board Member

◷ Joined April 2007▧ 341 Photos and videos
Niklas Klümper avatar
⟳ Axel S. Merseburger retweeted
Niklas Klümper@niklas_kluemper·17h

Excellent overview, David! 👏 @Dr_Aggen For me, switching ADC targets and payloads is among the most promising strategies after EV+pembrolizumab failure—alongside novel mechanisms such as radioligand therapies (RLTs) and T-cell engagers (TCEs). But a key biological question remains: Is NECTIN4 still a valid target after EV resistance? In NEXUS, EV-pretreated patients showed lower response rates than EV-naïve patients—a signal worth investigating further, although prior EV exposure does not necessarily imply loss of NECTIN4. There are so many potentially actionable cell-surface targets in urothelial cancer, many still largely unexplored. We need to understand both primary and acquired resistance biology to guide the next treatment, rather than simply switch drugs. 🧬 @OncoAlert @weoncologists @urotoday @Uromigos @OncoAlert and Faculty: @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @Markuseckstein3 x.com/dr_aggen/status/212237…

Post attachment
OncoAlert avatar
⟳ Axel S. Merseburger retweeted
OncoAlert@OncoAlert·Nov 13

Durvalumab (Imfinzi) + enfortumab vedotin-ejfv approved by the US FDA for muscle-invasive bladder cancer (MIBC) FDA announcement On November 13, 2026, the FDA approved neoadjuvant durvalumab + enfortumab vedotin-ejfv, followed by adjuvant durvalumab after radical cystectomy, for adults with MIBC who are cisplatin-ineligible or who refuse cisplatin-based chemotherapy. Based on the VOLGA trial (NCT04960709): • EFS: HR 0.51 (95% CI, 0.38–0.67; p<0.0001) Median EFS: not reached (95% CI, 33.2–NR) vs 12.1 months • OS: HR 0.58 (95% CI, 0.40–0.83; p=0.0027) Median OS: not reached in either arm A meaningful new option for patients who cannot receive or decline cisplatin. #BladderCancer #MIBC #EnfortumabVedotin #UromigosLive Pinging our faculty @DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper, @Markuseckstein3

Post attachment
OncoAlert avatar
⟳ Axel S. Merseburger retweeted
OncoAlert@OncoAlert·Nov 9

THE COMPLETE #ESMO26 NEWSLETTER 📰 Final Notice 👉 oncoalert360.com/newsletter/… Bringing together our top picks from the most important trials presented in Madrid, all in one email. Curated by oncologists, for colleagues in cancer care, our mission is to make the latest oncology science accessible, relevant, and easy to digest. We are OncoAlert 🚨 — For Colleagues, by Colleagues. Best, The OncoAlert Network @cdanicas @hoperugo @DrChoueiri @TiansterZhang @matteolambe @NiuSanford @stolaney1 @christine_lovly @amerseburger @GlopesMd @tompowles1 @montypal @Icro_Meattini @PGrivasMDPhD @brian_rini @CathyEngMD @apolo_andrea @AndreaNecchi @DrSGraff @BenWestphalen @graokane @to_be_elizabeth @ElisaAgostinett @nataliagandur @UOzkerim @DrMirallas @DrYukselUrun @Lucarecco @mzugman @HHorinouchi @p_ciracimd @DraMartinezLago @DrVilmaPBarcia @GIMedOnc @MarioBalsaMD @scocmem @AmandaNizamMD @GaiaGriguolo @JankovicK @Dr_Oncologista @Erman_Akkus @WeOncologists

Post attachment
Niklas Klümper avatar
⟳ Axel S. Merseburger retweeted
Niklas Klümper@niklas_kluemper·Nov 9

🚀 J&J is building one of the most exciting pipelines in prostate cancer! Impressive #SITC2026 data for pasritamig (KLK2×CD3) + JNJ-9401 (PSMA×CD28) in mCRPC. At the recommended regimen (n=15): 🎯 PSA50: 73% 🎯 PSA90: 47% 🎯 Undetectable PSA: 27% (4/15), with responses ongoing ≥6 months But what really stands out is tolerability: ✅ CRS in only 20% — all grade 1, transient fever only ✅ No tocilizumab required ✅ Outpatient dosing every 6 weeks! Combining CD3-mediated T-cell engagement with CD28 costimulation while targeting two distinct prostate cancer antigens is a fascinating strategy. Together with the super exciting RIPTAC technology and JNJ-6143, this highlights the breadth of J&J’s emerging prostate cancer immunotherapy pipeline. Could potent T-cell redirection finally become both effective AND manageable in routine clinical practice? Early phase, only 15 patients at the recommended regimen. Randomized validation and longer follow-up are essential. #ProstateCancer #Immunotherapy @MAWildgust @OncoAlert @weoncologists @urotoday @Uromigos @OncoAlert and Faculty: @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @Markuseckstein3

Post attachment
Zach Klaassen avatar
⟳ Axel S. Merseburger retweeted
Zach Klaassen@zklaassen_md·Oct 26

#ESMO26 Management of mCRPC: Personalized treatment selection and sequencing @dmukherji @urotoday Spectrum of PARPi sensitivity in mCRPC by HRR gene alteration Evidence from PROfound, MAGNITUDE, TALAPRO-2, PROpel, and FDA pooled analysis

Post attachment
onkowissen avatar
⟳ Axel S. Merseburger retweeted
onkowissen@onkowissen·Oct 22

Welche Daten werden die Behandlung von Prostata-, Nieren- und Harnblasenkarzinomen künftig prägen? Entdecken Sie die wichtigsten GU Highlights vom ESMO 2026 auf onkowissenTV. Experten analysieren aktuelle Studien und ordnen deren Bedeutung für die klinische Praxis ein.

OncoAlert avatar
⟳ Axel S. Merseburger retweeted
OncoAlert@OncoAlert·Nov 2

Visit Our New Website 🚨 Science Directly From the People Who Presented It 👉 oncoalert360.com/events/esmo… No noise. No ads. Just oncology, for colleagues, by colleagues. OncoAlert is with you every day, not just at congresses. Our website brings you the science you need to stay up to date, with no fluff, no distractions and no advertising. We are a non-profit Organization with one mandate: keeping colleagues worldwide up to date. For almost a decade, OncoAlert has been made 100% by physicians, by oncologists for oncologists. Some of the biggest names in oncology are part of this network, and they use it to bring new findings directly to you. @cdanicas · @hoperugo · @DrChoueiri · @TiansterZhang · @matteolambe · @NiuSanford · @stolaney1 · @christine_lovly · @amerseburger · @GlopesMd · @tompowles1 · @montypal · @Icro_Meattini · @PGrivasMDPhD · @brian_rini · @CathyEngMD · @apolo_andrea · @AndreaNecchi · @DrSGraff · @BenWestphalen · @graokane · @to_be_elizabeth · @ElisaAgostinett · @nataliagandur · @UOzkerim · @DrMirallas · @DrYukselUrun · @Lucarecco · @mzugman · @HHorinouchi · @p_ciracimd · @DraMartinezLago · @DrVilmaPBarcia · @GIMedOnc · @MarioBalsaMD · @scocmem · @AmandaNizamMD · @GaiaGriguolo · @JankovicK · @Dr_Oncologista · @Erman_Akkus · @WeOncologists · @niklas_kluemper · @Markuseckstein3

Post attachment
LARVOL avatar
⟳ Axel S. Merseburger retweeted
LARVOL@Larvol·Oct 29

@myESMO 2026: Top trending GU cancer oncologists on 𝕏. Explore #ESMO26 insights here: clin.larvol.com/conference/a… #LARVOL #ESMO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #MedicalOncology #ClinicalTrials #GUCancer #GUCSM #GenitourinaryCancer #KidneyCancer #BladderCancer #ProstateCancer #ClinicalOncology | @DrChoueiri | @tompowles1 | @DrYukselUrun | @DrKarineTawagi | @amerseburger | @nataliagandur | @AndreaNecchi | @Dr_Aggen | @ShingoHatakeya1 | @shilpaonc | @PGrivasMDPhD | @TiansterZhang | @HimanshuNagarMD | @Kenrickng1 | @drmutluhizal

Post attachment
OncoAlert avatar
⟳ Axel S. Merseburger retweeted
OncoAlert@OncoAlert·Oct 28

Why ‘More Drugs’ Isn’t Always Better: VOLGA Trial Redefines #BladderCancer Care #Podium2Screen from the #ESMO26 Presidential Session Presented by our @OncoALert 🚨faculty @tompowles1 Perioperative Durvalumab ± Tremelimumab Plus Neoadjuvant Enfortumab Vedotin in Muscle-Invasive Bladder Cancer: Results From the Phase 3 VOLGA Trial @jteoh_hk @CPRT65 🔬 Phase 3 VOLGA trial (n=695) Evaluated perioperative durvalumab (D) ± tremelimumab (T) plus neoadjuvant enfortumab vedotin (EV) versus control (radical cystectomy [RC], followed by observation or approved adjuvant therapy) in cisplatin-ineligible muscle-invasive bladder cancer (MIBC). Just PUBLISHED in @NEJM nejm.org/doi/full/10.1056/NE… Interim analysis; median event-free survival (EFS) follow-up: 22.9 months. ➡️ D + EV: EFS HR 0.51 (95% CI, 0.38–0.67); OS HR 0.58 (95% CI, 0.40–0.83) ➡️ D + T + EV: EFS HR 0.61 (95% CI, 0.47–0.80); OS did not meet statistical significance ➡️ Pathological complete response (pCR): 45% with D + EV vs 10% with control ➡️ Grade 3/4 treatment-related adverse events (TRAEs): 30% with D + EV vs 42% with control ✅ Both primary EFS endpoints were met. Perioperative durvalumab plus 3 cycles of neoadjuvant EV also significantly improved OS. 🎙️ Presenter: Thomas Powles 👥 Investigators: Alexandra Drakaki · Jeremy Teoh · Enrique Grande · Mario Fontes-Sousa · Camillo Porta · Esther Wu · Erik Goluboff · Svetlana Ho · Stephan Hois · Ashok Gupta · James Catto @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @niklas_kluemper @Markuseckstein3

0:56
OncoAlert avatar
⟳ Axel S. Merseburger retweeted
OncoAlert@OncoAlert·Oct 28

Thank you Colleagues for a phenomenal #ESMO26 ESMO in Madrid is a wrap, and we are grateful to everyone who shared, discussed, debated and amplified the science this week. You turned five days in Madrid into a truly global conversation. 🌍 OUR Network's MISSION: Keep our colleagues worldwide Up To date in REAL TIME. 📣 101.7M impressions of potential reach 💬 6.1K posts on X from 988 participants in 34 countries ⚡ 43.1 posts per hour across the meeting days 😊 45% positive sentiment, with only 6% negative Real-time metrics powered by ACUVOX. WWW.ACUVOX.IO 🏆 Top influencers @DrChoueiri, @StephenVLiu, @PTarantinoMD, @dr_yakupergun, @HHorinouchi, @zklaassen_md, @stolaney1, @ArndtVogel, @DrYukselUrun, @DraMartinezLago, @tompowles1, @SuyogCancer, @adamfeuerstein, @ScaltritiLab, @GIMedOnc, @ScottGottliebMD, @barriere_dr, @_ShankarSiva, @miriamgonp, @TiansterZhang, @matteolambe, @NiuSanford, @christine_lovly, @amerseburger, @GlopesMd, @montypal, @Icro_Meattini, @PGrivasMDPhD, @brian_rini, @CathyEngMD, @apolo_andrea, @AndreaNecchi, @DrSGraff, @graokane, @to_be_elizabeth, @ElisaAgostinett, @nataliagandur, @UOzkerim, @DrMirallas, @Lucarecco, @mzugman, @p_ciracimd, @DrVilmaPBarcia, @MarioBalsaMD, @scocmem, @GaiaGriguolo, @JankovicK, @Dr_Oncologista 🌎 Where the conversation came from North America led with 1,940 posts, followed closely by Europe with 1,777. Boston, Madrid and New York were the most active cities. 🔬 Top studies by impact 1️⃣ DeLLphi-305 (SCLC): 4.0M reach, 170 posts 2️⃣ VOLGA (bladder): 3.7M reach, 141 posts 3️⃣ KRASCENDO-1 (NSCLC): 3.5M reach 4️⃣ SAFFRON (NSCLC): 3.3M reach 5️⃣ INTerpath-001 (melanoma): 154 posts Pinging our Collaborators

Post attachment